Can AI replace medical writers? Experts say not immediately
AI is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but those using…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
Saving shelved ultra-rare therapies through unorthodox funding
As a funding drought for biopharma is on the horizon, non-profit biotech Orphan Therapeutics Accelerator is championing an innovative funding…
-
Amid deglobalising trade, experts seek AI safeguards for clinical trial supply
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial…
-
Are European biopharma manufacturers ‘nearshoring’?
In step with international news in recent times, European pharma and biotech are leaning towards ‘nearshoring’, preferring domestic operations to…
-
Machine learning adoption into supply chain management on the horizon
Widespread integration of machine learning (ML) into supply chain management by major pharma suppliers is just a few years away,…
-
New EU trial regulations could expedite approvals and address shortages
A major overhaul and consolidation of EU clinical trial regulations is paving the way to faster approvals, greater international coordination,…
-
Mandatory drug stock monitoring empowers EU to tackle shortages
Earlier this month, the newly empowered role of the European Union (EU)’s Executive Steering Group on Shortages and Safety of…
-
Supply chain uncertainties present opportunities for biopharma couriers in 2025
Despite concerns of supply chain fragility as geopolitical tensions mount, global biopharma courier Biocair is braced for a surge in…
-
Supply chains and AI take precedence at European clinical trial meeting
As global supply chains come under increasing strain and AI disrupts how clinical trials are conducted, experts will congregate to…
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for…
